Chung-Pu Wu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3561023/publications.pdf

Version: 2024-02-01

75 papers	3,912 citations	147801 31 h-index	123424 61 g-index
75 all docs	75 docs citations	75 times ranked	5444 citing authors

#	Article	IF	Citations
1	Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research, 2008, 68, 7905-7914.	0.9	362
2	Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Research, 2010, 70, 7981-7991.	0.9	297
3	Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. Journal of the National Cancer Institute, 2010, 102, 1637-1652.	6.3	241
4	Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies. Current Molecular Pharmacology, 2008, 1, 93-105.	1.5	229
5	Development of inhibitors of ATP-binding cassette drug transporters â€“ present status and challenges. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 205-223.	3.3	225
6	The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy. Molecular Pharmaceutics, 2011, 8, 1996-2011.	4.6	199
7	Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy. Current Pharmaceutical Biotechnology, 2011, 12, 609-620.	1.6	150
8	Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and) Tj ETQq0 0 0 rgBT /Overlock 10	4.7	141
9	Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemotherapy and Pharmacology, 2006, 57, 376-388.	2.3	100
10	Novel Dengue Virus-Specific NS2B/NS3 Protease Inhibitor, BP2109, Discovered by a High-Throughput Screening Assay. Antimicrobial Agents and Chemotherapy, 2011, 55, 229-238.	3.2	100
11	Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistanceâ€“linked ABCG2 transporter. Molecular Cancer Therapeutics, 2007, 6, 3287-3296.	4.1	89
12	Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neuro-Oncology, 2012, 14, 1227-1238.	1.2	87
13	Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochemical Pharmacology, 2013, 85, 325-334.	4.4	70
14	Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. Biochemical Pharmacology, 2005, 70, 500-510.	4.4	61
15	The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistanceâ€“linked ATP binding cassette drug transporter ABCG2. Molecular Cancer Therapeutics, 2007, 6, 3279-3286.	4.1	60
16	ABC Drug Transporters as Molecular Targets for the Prevention of Multidrug Resistance and Drug-Drug Interactions. Current Drug Delivery, 2007, 4, 324-333.	1.6	59
17	NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme. Free Radical Biology and Medicine, 2012, 53, 649-658.	2.9	58
18	Livin Contributes to Tumor Hypoxiaâ€“Induced Resistance to Cytotoxic Therapies in Glioblastoma Multiforme. Clinical Cancer Research, 2015, 21, 460-470.	7.0	58

#	Article	IF	Citations
19	Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2010, 80, 1497-1506.	4.4	57
20	Cycling hypoxia induces chemoresistance through the activation of reactive oxygen species-mediated B-cell lymphoma extra-long pathway in glioblastoma multiforme. Journal of Translational Medicine, 2015, 13, 389.	4.4	57
21	cGMP and glutathione-conjugate transport in human erythrocytes. The roles of the multidrug resistance-associated proteins, MRP1, MRP4 and MRP5. FEBS Journal, 2003, 270, 3696-3708.	0.2	55
22	Plasmodium falciparum expresses a multidrug resistance-associated protein. Biochemical and Biophysical Research Communications, 2004, 321, 197-201.	2.1	54
23	Complete Inhibition of the Pdr5p Multidrug Efflux Pump ATPase Activity by Its Transport Substrate Clotrimazole Suggests that GTP as Well as ATP May Be Used as an Energy Source. Biochemistry, 2007, 46, 13109-13119.	2.5	52
24	Synthesis and Characterization of a BODIPY Conjugate of the BCR-ABL Kinase Inhibitor Tasigna (Nilotinib): Evidence for Transport of Tasigna and Its Fluorescent Derivative by ABC Drug Transporters. Molecular Pharmaceutics, 2011, 8, 1292-1302.	4.6	49
25	Avapritinib: A Selective Inhibitor of KIT and PDGFRÎ± that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Molecular Pharmaceutics, 2019, 16, 3040-3052.	4.6	49
26	The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharmaceutica Sinica B, 2014, 4, 105-111.	12.0	48
27	Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro. Molecular Pharmaceutics, 2016, 13, 2117-2125.	4.6	42
28	Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Molecular Cancer Therapeutics, 2009, 8, 2057-2066.	4.1	41
29	Reversal of chloroquine resistance in Plasmodium falciparum by 9H-xanthene derivatives. International Journal of Antimicrobial Agents, 2005, 26, 170-175.	2.5	40
30	Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. Biochemical Pharmacology, 2013, 86, 904-913.	4.4	39
31	Human Immunodeficiency Virus Protease Inhibitors Interact with ATP Binding Cassette Transporter 4/Multidrug Resistance Protein 4: A Basis for Unanticipated Enhanced Cytotoxicity. Molecular Pharmacology, 2013, 84, 361-371.	2.3	38
32	Tumor Hypoxia Regulates Forkhead Box C1 to Promote Lung Cancer Progression. Theranostics, 2017, 7, 1177-1191.	10.0	32
33	Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1. Molecular Pharmaceutics, 2015, 12, 3885-3895.	4.6	31
34	Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2. Biochemical Pharmacology, 2014, 92, 567-576.	4.4	29
35	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. Molecular Pharmaceutics, 2016, 13, 784-794.	4.6	29
36	The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Cancer Letters, 2019, 445, 34-44.	7.2	28

#	Article	IF	Citations
37	Mammalian target of rapamycin signaling is a mechanistic link between increased endoplasmic reticulum stress and autophagy in the placentas of pregnancies complicated by growth restriction. Placenta, 2017, 60, 9-20.	1.5	27
38	Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochemical Pharmacology, 2009, 78, 355-364.	4.4	26
39	Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Cancers, 2020, 12, 195.	3.7	25
40	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products, 2020, 83, 1461-1472.	3.0	25
41	Dependence of Multidrug Resistance Protein-Mediated Cyclic Nucleotide Efflux on the Background Sodium Conductance. Molecular Pharmacology, 2010, 77, 270-279.	2.3	24
42	Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. Molecular Pharmaceutics, 2017, 14, 2805-2814.	4.6	24
43	Overexpression of Human ABCB1 in Cancer Cells Leads to Reduced Activity of GSK461364, a Specific Inhibitor of Polo-like Kinase 1. Molecular Pharmaceutics, 2014, 11, 3727-3736.	4.6	23
44	The Use of PET Imaging for Prognostic Integrin Î±₂Î²₁ Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses. Theranostics, 2017, 7, 4013-4028.	10.0	23
45	Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. Cancers, 2020, 12, 1366.	3.7	23
46	cGMP (guanosine 3â€²,5â€²-cyclic monophosphate) transport across human erythrocyte membranes. Biochemical Pharmacology, 2005, 69, 1257-1262.	4.4	22
47	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochemical Pharmacology, 2012, 84, 766-774.	4.4	22
48	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1. Journal of Natural Products, 2016, 79, 2135-2142.	3.0	22
49	Plasma membrane calcium ATPase (PMCA4): a housekeeper for RT-PCR relative quantification of polytopic membrane proteins. BMC Molecular Biology, 2006, 7, 29.	3.0	21
50	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Molecular Pharmacology, 2016, 89, 263-272.	2.3	21
51	The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochemical Pharmacology, 2021, 188, 114516.	4.4	21
52	SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Letters, 2018, 433, 259-272.	7.2	19
53	Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology, 2020, 180, 114137.	4.4	19
54	Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Letters, 2017, 409, 56-65.	7.2	18

#	Article	IF	Citations
55	In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. Biochemical Pharmacology, 2011, 82, 1562-1571.	4.4	17
56	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochemical Pharmacology, 2018, 155, 316-325.	4.4	16
57	Resistance Analysis and Characterization of a Thiazole Analogue, BP008, as a Potent Hepatitis C Virus NS5A Inhibitor. Antimicrobial Agents and Chemotherapy, 2012, 56, 44-53.	3.2	13
58	Decreased placental apoptosis and autophagy in pregnancies complicated by gestational diabetes with large-for-gestational age fetuses. Placenta, 2020, 90, 27-36.	1.5	13
59	Noninvasive imaging of heart chamber in Drosophila with dualâ€beam optical coherence tomography. Journal of Biophotonics, 2013, 6, 708-717.	2.3	11
60	Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells. Molecular Pharmaceutics, 2017, 14, 2368-2377.	4.6	11
61	The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences, 2020, 21, 238.	4.1	10
62	Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. International Journal of Molecular Sciences, 2021, 22, 2592.	4.1	9
63	Micronized progesterone pretreatment affects the inflammatory response of human gestational tissues and the cervix to lipopolysaccharide stimulation. Placenta, 2017, 57, 1-8.	1.5	7
64	The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines. Cancer Letters, 2018, 434, 81-90.	7.2	7
65	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products, 2021, 84, 2544-2553.	3.0	7
66	Differential Changes in Akt and AMPK Phosphorylation Regulating mTOR Activity in the Placentas of Pregnancies Complicated by Fetal Growth Restriction and Gestational Diabetes Mellitus With Large-For-Gestational Age Infants. Frontiers in Medicine, 2021, 8, 788969.	2.6	6
67	P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhibitor Ensartinib in Cancer Cells. Cancers, 2022, 14, 2341.	3.7	6
68	MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. American Journal of Cancer Research, 2020, 10, 164-178.	1.4	5
69	The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biomedicine and Pharmacotherapy, 2022, 149, 112922.	5.6	4
70	Branebrutinib (BMS-986195), a Brutonâ€™s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. Frontiers in Cell and Developmental Biology, 2021, 9, 699571.	3.7	3
71	The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences, 2021, 22, 9440.	4.1	3
72	Increased Soluble Epoxide Hydrolase in Human Gestational Tissues from Pregnancies Complicated by Acute Chorioamnionitis. Mediators of Inflammation, 2019, 2019, 1-13.	3.0	2

#	Article	IF	Citations
73	Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors. , 2019, , 169-185.		1
74	Isoreserpine Reverses Multidrug Resistance Mediated by ABCB1. Journal of Cancer Research Updates, 2015, 4, 188-194.	0.3	0
75	SIS3, a specific inhibitor of Smad3, reverses multidrug resistance mediated by ABCB1 and ABCG2 in cancer cell lines. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-24.	0.0	0